Adjunctive aripiprazole in bipolar I depression

Annals of Pharmacotherapy

Volumn 41, Issue 1, 2007, Pages 35-40

  Sokolski, Kenneth N ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA LONG BEACH HEALTHCARE SYSTEM   (United States)

Author keywords

Aripiprazole; Atypical antipsychotics; Bipolar depression

Indexed keywords

ARIPIPRAZOLE; CLONAZEPAM; FLUPHENAZINE; GABAPENTIN; HALOPERIDOL; HALOPERIDOL DECANOATE; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; OLANZAPINE; PAROXETINE; PROPRANOLOL; QUETIAPINE; RISPERIDONE; TRAZODONE; VALPROATE SEMISODIUM; VENLAFAXINE;

ADULT; AGED; AKATHISIA; ANXIETY; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR MANIA; CLINICAL GLOBAL IMPRESSION SCALE; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; HUMAN; INSOMNIA; MAINTENANCE THERAPY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; SOMNOLENCE; STATISTICAL ANALYSIS;

ADULT; AGED, 80 AND OVER; BIPOLAR DISORDER; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; RETROSPECTIVE STUDIES;

EID: 33846443623     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H294     Document Type: Article

References (26)

1. Post RM, Calabrese JR. Bipolar depression: the role of atypical antipsychotics. Expert Rev Neurother 2004;4(suppl):S27-33.
2. Ghaemi SN, Rosenquist KJ, Ko JY, Baldassano CF, Kontos NJ, Baldessarini RJ. Antidepressant treatment in bipolar disorder versus unipolar depression. Am J Psychiatry 2004;161:163-5.
3. Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2004;64:1013-24.
4. Ernst CL, Goldberg JF. Antidepressant properties of anticonvulsant drugs for bipolar disorder. J Clin Psychopharmacol 2003;23:182-92.
5. Perlis RH, Welge JA, Vornik LA, Hirshfeld RM, Keck PE. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry 2006;67:509-16.
6. Keck PE. Bipolar depression: a new role for atypical antipsychotics? Bipolar Disord 2005;7(suppl):S34-40.
7. Gao K, Gajwani P, Elhaj O, Calabrese JR. Typical and atypical antipsychotics in bipolar depression. J Clin Psychiatry 2005;66:1376-85.
8. Nierenberg AA, Ostacher MJ, Calabrese J, et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry 2006;163:210-6.
9. Ketter TA, Wang PW, Chandler RA, Culver JL, Alarcon AM. Adjunctive aripiprazole in treatment-resistant bipolar depression. Ann Clin Psychiatry 2006;18:169-72.
10. 2 receptor partial agonist. J Med Invest 2005;(suppl):S284-90.
11. DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 2004;26:649-66.
12. Barbee JG, Conrad EJ, Jamhour NJ. Aripiprazole augmentation in treatment-resistant depression. Ann Clin Psychiatry 2004;16:189-94.
13. Hellerstein DJ. Aripiprazole as an adjunctive treatment for refractory major depression. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:1347-8.
14. Papakostas GI, Petersen TJ, Kinrys G, et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry 2005;66:1326-30.
15. Simon JS, Nemeroff CB. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J Clin Psychiatry 2005;66:1216-20.
16. 1A agonist properties on PCP-induced social interactions in the rat. Neuropharmacol 2005;49:996-1006. Epub 11 Jun2005.
17. Zocchi A, Fabbri D, Heidbreder CA. Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex. Neurosci Lett 2005;387:157-61.
18. Tremblay LK, Naranjo CA, Graham SJ, et al. Functional neuroanatomical substrates of altered reward processing in major depressive disorder revealed by a dopaminergic probe. Arch Gen Psychiatry 2005;62:1228-36.
19. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th revision. Washington, DC: American Psychiatric Association, 2000.
20. Pinninti NR, Madison H, Musser E, Rissmiller D. MINI International Neuropsychiatric Schedule: clinical utility and patient acceptance. Eur Psychiatry 2003;18:361-4.
21. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9.
22. Barzman DH, DelBello MP, Kowatch RA, et al. The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review. J Child Adolesc Psychopharmacol 2004;14:593-600.
23. Hirschfeld RM, Vornik LA. Bipolar disorder-costs and comorbidity. Am J Manag Care 2005;11(suppl):S585-90.
24. Baldessarini RJ, Pompill M, Tondo L. Suicide in bipolar disorder: risks and management. CNS Spectre 2006;11:465-71.
25. Keck PE, Nelson EB, McElroy SL. Advances in the pharmacologic treatment of bipolar disorder. Biol Psychiatry 2003;53:671-9.
26. Goodwin FK. Rationale for using lithium in combination with other mood stabilizers in the management of bipolar disorder. J Clin Psychiatry 2003;64(suppl):S18-24.